Zacks Investment Research
07 Aug 2026, 18:36 UTC · 3h ago
Halozyme's Q2 Earnings Beat Estimates, 2026 Outlook Raised, Stock Up
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Zacks Investment Research
07 Aug 2026, 18:36 UTC · 3h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
4 claims · each scored for market impact
Halozyme Therapeutics reported Q2 2026 adjusted earnings of $2.28 per share, significantly beating the $1.82 consensus estimate. — A substantial earnings beat typically triggers a positive price correction as it signals stronger profitability than analysts expected.
+0.60Halozyme's Q2 2026 total revenues increased 48% year-over-year to $481 million, surpassing the $410 million estimate. — Strong top-line growth and a revenue beat indicate robust demand for the company's technology and products.
+0.50The company increased its full-year 2026 outlook following the strong quarterly results. — Guidance raises are highly valued by markets as they suggest the current growth trajectory is sustainable for the remainder of the year.
+0.40Continue reading
6 related stories
Top 3 movers · tap to explore
Royalty revenues grew 50% year-over-year to $307.7 million, driven by demand for J&J's Darzalex and argenx's Vyvgart Hytrulo. — Growth in high-margin royalty streams improves the quality of earnings and validates the utility of Halozyme's Enhanze technology.
+0.30Which stocks this story touches
Reported Q2 earnings and revenues that beat estimates, with significant year-over-year growth and an increased 2026 outlook.
Mentioned as having robust demand for subcutaneous Darzalex, contributing to royalty payments for a partner.
Mentioned as having robust demand for Vyvgart Hytrulo, contributing to royalty payments for a partner.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
New York Post
1h ago
